Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdvanTIG-205 in first-line metastatic NSCLC
2021-001075-17Phase 2Active
- Sponsor
- BeiGene
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ociperlimab + tislelizumab + chemotherapy with Placebo + tislelizumab + chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Mar 2022; status: active.
02
Drugs
ociperlimabtislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-001075-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001075-17.